Oalib Open Access Library Journal 2333-9705 2333-9721 Scientific Research Publishing 10.4236/oalib.1113515 Oalib-143243 Articles Biomedical Life Sciences, Business Economics, Chemistry Materials Science, Computer Science Communications, Earth Environmental Sciences, Engineering, Medicine Healthcare, Physics Mathematics, Social Sciences Humanities Machine Learning Analysis of Pramipexole Augmentation in Treatment-Resistant Depression: Identifying Predictors of Response Rocco de Filippis 1 Abdullah Al Foysal 2 aDepartment of Neuroscience, Institute of Psychopathology, Rome, Italy aDepartment of Computer Engineering (AI), University of Genova, Genova, Italy 05 06 2025 12 06 1 16 25, April 2025 10, April 2025 10, June 2025 © Copyright 2014 by authors and Scientific Research Publishing Inc. 2014 This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Background: Treatment-resistant depression (TRD) poses significant clinical challenges, with many patients inadequately responding to augmentation strategies like aripiprazole. Pramipexole, a dopamine agonist, has emerged as a promising alternative, though predictors of response remain unclear. This study applies machine learning (ML) to identify predictors and subgroups influencing pramipexole augmentation (PA) effectiveness in TRD, especially among patients previously failing aripiprazole augmentation (FAA). Methods: A synthetic dataset (n = 500), based on real-world data, comprised FAA (n = 150) and aripiprazole-untreated (UAA, n = 350) groups. Four ML algorithms (Random Forest, Gradient Boosting, Logistic Regression, SVM) predicted treatment response. Model accuracy, ROC curves, calibration, feature importance (via SHAP), and patient clustering (k-means) were evaluated. Results: Response rates were higher in UAA (76.9%) versus FAA (66.2%). SVM had the highest accuracy (73.3%), while Logistic Regression showed the best discrimination (ROC AUC = 0.612) and calibration. Key predictors included baseline depression severity, episode duration, pramipexole dosage, and patient age, with significant age-dose interactions. Clustering revealed younger FAA patients with prolonged depressive episodes as a high-risk subgroup with notably lower remission rates (49%). Conclusions: ML analysis highlights baseline depression severity, age, episode duration, and pramipexole dosage as crucial predictors of PA response. Younger FAA patients with extended depressive episodes represent a high-risk subgroup needing tailored therapeutic strategies, reinforcing precision psychiatry for managing complex TRD cases.Subject AreasArtificial Intelligence, Psychiatry&Psychology Treatment-Resistant Depression Pramipexole Augmentation Machine Learning Predictive Modelling Precision Psychiatry 1. 引言近年来，随着多媒体技术和经济多元全球化的不断发展，跨界思维不断冲击着传统的品牌联合，电商、餐饮、服装等行业相继掀起跨界联合风潮，营销学之父菲利普·科特勒曾经说过：除了主流品牌和小众品牌以外，混合品牌也将在未来占据一席之地，其中这个混合品牌与后面的“跨界品牌联合”在某种程度上是一样的，跨界品牌联合是指处于不同行业边界的品牌跨边界进行合作共同推出新产品 [1] 。在跨界联合的实践过程中有的品牌跨界备受关注，溢出效应明显，例如Rio华为手机结合保时捷设计出的超级旗舰MateRS设计好评如潮，大白兔品牌奶糖与加美净这类日化品牌推出的奶糖味的唇膏，上架即一扫而光，然而有的跨界联合却反响平平，甚至出现负面溢出效果，例如喜茶与杜蕾斯的联合产品没有得到消费者的积极评价，甚至使消费者产生反感情绪。之前关于品牌联合效果影响因素的分析上主要体现在联合匹配性、在产品关系和逻辑上的契合度，以及品牌要素互补性方面，但是在研究跨界联合时没有考虑到跨界品牌双方本身就具有较大的差异性，所以在一定程度上对跨界联合的成败现象并不能完全解释。因此，本文聚焦品牌跨界联合情景下，根据形式与功能的整合程度将品牌跨界联合的整合度分为高、低两种，基于SOR模型 [2] ，进而分析品牌跨界联合时的整合度高低对消费者品牌联合评价的影响机制，并且在这个基础上研究消费者感知价值在品牌跨界联合时的整合度对消费者品牌联合评价的中介作用。 2. 文献回顾及研究假设(一) 品牌跨界联合整合度与消费者品牌联合评价相关研究有关品牌跨界联合的概念大多围绕跨界营销进行，在市场营销中有共生营销的概念，它是指一种合作联盟关系，合作双方及多方为实现资源共享，提升竞争能力而形成的一种长期或者短期联盟合作关系，而品牌跨界联合则是指两个异质行业、互相独立但拥有平等商业地位的品牌通过活化老品牌，共享互补资源，降低成本等方式以推出新产品，从而实现销售额的增加 [3] 。两者具有一定的相似性，因此根据前人的论述及本文的研究内容将品牌跨界联合大致定义为品牌联合的特殊形式，是指同一个新的产品中存有两个来自不同且没有竞争关系行业的品牌。由于合作品牌双方的合作程度对消费者的品牌评价会产生相应的影响，Newmeyer等(2018) [4] 根据联合产品在形式和功能上的结合程度提出了六种整合度不同的品牌联合形式，从低到高依次为同地品牌联合、共同促销、捆绑联合、成分联合、要素联合、共同研发联合，本文根据形式和功能的结合程度，将共同研发联合和元素联合划分为高度整合，成分联合和捆绑联合划分为中度整合，共同促销和同地品牌联合划分为低度整合。一个品牌产品所带来的功能或者形式较为单一，不能满足消费者日益多元的功能需求和价值需求，如果将两个异质性产品进行跨界联合，不仅能够带来冲击固有认知的创新感，还有益于提升消费者的忠诚度，但是差异过大的品牌联合可能会产生负面溢出效应 [5] 。所以大多学者聚焦于品牌跨界联合前的联合匹配性和契合度的研究，忽视了品牌跨界联合过程中的整合程度，而消费者对跨界品牌联合的评价在一定层面上反映出跨界联合双方合作的效果，较高的评价不仅有助于维持对品牌资产较好品牌的忠诚度，还有利于提升品牌资产较弱一方的品牌形象(Lin, 2013)，在跨界品牌联合中合作双方的交融程度越深，即产品整合度越高，越有益于消费者体验到品牌双方各自的优势，感受到跨界联合产品所带来的新奇与价值感，从而促进消费者对跨界品牌联合作出积极评价。综上所述，本文提出假设1：H1：在品牌跨界联合时，产品整合度对品牌联合评价有正向影响。(二) 在品牌跨界联合时，感知价值在产品联合整合度对品牌联合评价中的中介作用消费者感知价值这一概念是基于现代营销中的消费者价值理论，该理论认为营销其实是交换价值与感知价值的过程，消费者在得到产品后会对其付出成本与感知价值效用进行比较，从而给出整体评价 [6] 。消费者感知价值时往往有三个特征，对产品价值会根据自身主观性进行感知，并且倾向于在比较中感知价值，其感知的价值还具有阶梯性 [7] 。因此，范秀成等(2003) [8] 将消费者感知价值概述为消费者对企业提供的产品和服务价值的主观评价，当消费者感知到价值时会对品牌联合产生积极评价，而产品整合度越高，即跨界联合产品无论是形式还是功能方面都高度融合，没有令消费者产生突兀感，能够驱动消费者产生价值感知，将异质的产品进行创新融合，起初的不匹配性能够打破了对原有品牌的刻板印象，再通过后面的高度整合能够使消费者产生创新感知的同时降低跨界创新产品的不确定性，感受到品牌联合带来的综合价值，而消费者的感知价值会影响消费者对品牌的选择，进而促进消费者对品牌联合作出正向评价 [9] 。因此，本文假设在品牌跨界联合过程中，合作双方后期在形式和功能上的产品整合度将影响消费者感知价值，又因为高整合度与品牌联合评价具有正向影响，推测消费者感知价值也将正向影响品牌联合评价。综上所述，本文提出假设2：H2：在品牌跨界联合时，消费者感知价值在产品整合度对消费者品牌联合评价的影响中起到中介作用。基于此，本文以SOR模型为研究框架，将品牌框架联合时的产品整合度作为刺激源，消费者从中获得的价值感知作为个体心理呈现，消费者对品牌联合的评价作为消费者者反应，构建在品牌跨界联合中产品整合程度对品牌联合评价的影响模型，模型如 图1 所示。 <xref ref-type="bibr" rid="oalib.143243-"></xref>Figure 1. Research model图1. 研究模型 图1. 研究模型 3. 实证设计与研究发现1) 研究设计与数据收集这部分由前测和正式实验组成，前测主要是通过了解市场上影响较广的跨界联合产品，并由此确定实验对象，正式实验根据产品组合利用单因素两水平，即产品整合程度高低的组间设计，检验品牌跨界联合时产品整合程度对品牌联合评价的主要影响以及消费者价值感知对其中的中介效应。① 前测。通过网络咨询了解与品牌跨界词条有关的内容，其中包含了有关跨界产品组合功能与形式的324条记录。选择了6组市面上真实的跨界组合案例，分别为蔻驰皮革的贝克家具、加入当尼柔顺剂的汰渍洗衣液、安装劳斯莱斯发动机的空客机、戴尔电脑与佳能打印机、配有迪士尼玩具的儿童餐、出售赛百味三明治的沃尔玛。通过变动产品整合度的操纵方法，让受访者填写整合度的7级量表 [4] ，对这些组合的产品整合度进行打分。此次前测收回有效问卷78份，并通过统计数据分析得出，蔻驰皮革的贝克家具这组共同研发组合的整合度评分均值为M 整合度 = 5.26，出售赛百味三明治的沃尔玛这组同地品牌联合销售的整合度评分均值为M 整合度 = 4.14，两者之间的差异很明显，将蔻驰皮革的贝克家具作为高整合度组合，而将出售赛百味三明治的沃尔玛作为低整合度组合，并将两组组合作为实验的刺激源。② 正式实验。该实验采用单因素两水平的设计，包括了102名消费者，其中人员年龄集中于26~35岁，男性占比42.15%，女性占比57.85%，教育程度占比主要是本科学历，将被试进行随机等量分配，其中高低整合度组各自均为61人。让产品高整合度组的被试浏览蔻驰皮革的贝克家具在功能和形式上的整合材料信息，同时让产品低整合度组的被试浏览沃尔玛出售赛百味三明治的销售整合信息，两组被试在看到品牌跨界联合刺激材料后如实填写产品感知价值量表以及品牌联合评价量表，具体量表题项如 表1 所示。 <xref ref-type="bibr" rid="oalib.143243-"></xref>Table 1. Measurement scaleTable 1. Measurement scale 表1. 测量量表

测量维度

测量题项参考来源

消费者感知价值

讨论/拥有/分享这项联名让我很开心

李慧，周雨(2021)

讨论/拥有/分享这项联名让我给他人留下了好印象

这项联名让我获得了自我满足

Sweeney and Soutar (2001)

该联名是我喜欢的

讨论/拥有/分享这项联名让我结识了很多朋友

品牌联合评价

我认为该产品很吸引人

Shih等(2013)

我非常喜欢该联合产品

该联合产品表达了我的个性
2) 数据分析① 问卷的信效度检验。利用SPSS 24.0对实验中的数据进行信度与效度的检验，其中产品感知价值量表以及品牌联合评价量表的Cronbach’ α系数分别为0.891、0.912，两者均在0.8以上，说明问卷信度较好。同时，通过验证性因子分析得出组合的CR和AVE值，从中发现组合效度AR值大于0.7，说明所选题项的一致性好，AVE值也达到了推荐的标准，所以该变量具有较好的效度。②主效应检验。在品牌跨界联合中，通过独立样本T检验验证产品整合度对消费者品牌联合评价有显著影响，即主效应检验。如 表2 所示，产品整合度不同，消费者对品牌跨界联合评价也显著不同，在产品整合度较高的跨界联合中，消费者对品牌联合评价(M = 2.811)显著高于产品整合度低的跨界联合产品(M = 1.649)，因此本文的假设1得到验证，即在品牌跨界联合时，产品整合度对品牌联合评价有正向影响。 <xref ref-type="bibr" rid="oalib.143243-"></xref>Table 2. Comparison of consumers’ evaluation of co-brand under different product integration degreesTable 2. Comparison of consumers’ evaluation of co-brand under different product integration degrees 表2. 不同产品整合度下消费者对品牌联合评价的差异比较

整合度分组

个案数

平均值

标准差

T值

品牌联合评价

高整合度

61

2.811

0.678

−5.650***

低整合度

61

1.649

0.718
③ 中介效应检验。本文以跨界产品整合度为自变量、消费者感知价值为中介变量、品牌联合评价为因变量，运用PROCESS程序中的model 4，通过Bootstrap方法对感知价值的中介效应进行检验，其中控制性别、年龄等人口特征变量。结果显示，产品整合程度对品牌联合评价的总效应为0.942，95%置信区间为(0.642, 1.193)，直接效应为0.401，95%置信区间为(0.076, 0.723)，均不包括0，产品整合程度对消费者感知价值具有显著的正向影响[B = 1.231, 95%置信区间为(0.844, 1.713), SE = 0.231, t = 5.895, p < 0.01]，消费者感知价值对品牌联合评价具有显著正向影响[B = 0.449, 95%置信区间为(0.289, 0.589), SE = 0.071, t = 6.334, p < 0.01]，从产品整合度到感知价值，再到品牌联合评价，其中的间接效应为0.673，95%的置信区间(0.302, 0.937)，不含0，由此得以验证感知价值在产品整合程度与品牌联合评价关系里起到中介作用。 4. 结论与启示本文通过实证分析研究了处于品牌跨界联合中，产品整合度对品牌联合评价的影响关系，主要得到两个结论：首先，在品牌跨界联合时，相比于产品整合度较低的跨界组合，产品整合度高的跨界组合更能够带来积极的品牌联合评价，即产品整合度对品牌联合评价有正向影响；其次，消费者感知价值在跨界产品整合度对品牌联合评价的影响中起到中介作用。通过实证研究，发现产品整合度越高，越有利于消费者感知价值，同时当消费者感知价值以后会对品牌联合作出积极评价，即消费者感知价值在跨界产品整合度和品牌联合评价中起到中介作用。而SOR理论正是关于刺激对个体心理产生影响，从而产生反应的研究模型，因此本文基于SOR理论，在品牌跨界联合时，产品整合度高这一刺激源使得消费者根据偏好流畅性的心理会降低对跨界创新产品的不确定性，从而增强消费者对该类商品的接受度，并从中感知到联合的综合价值。当消费者感受到情绪价值或者社会价值时会产生积极反应，即较高的品牌联合评价，这不仅维持了消费者对原有品牌产品的忠诚度，又在一定程度上提升了品牌资产，为企业有针对性地进行品牌跨界联合提供了感知价值角度的理论支持。本文的研究为企业进行跨界创新实践活动提供了相应指导。首先，尽管市场上出现的跨界创新现象层出不穷，与不同的品牌进行跨界创新能够在短期内快速吸引消费者，并从长期唤起品牌活力，提升品牌创新能力，但是在这个过程中企业应该结合自身的发展情况和战略模式进行调整，不要跟风进行盲目跨界。合适的跨界能够带来正面效应，但是如果缺少跨界的前提情景和适宜时机，跨界将给企业的发展带来无论是品牌形象还是消费者受众都产生消极影响。其次，在品牌跨界联合时，除了考虑前期匹配性，还需要进行整合度的规划。许多企业在进行品牌联合时往往考虑合作双方固有的形象或者市场是否匹配，匹配性较大可以提升消费者的可接受度，但是也可能固化消费者认知。对于需要进行品牌跨界转型的企业来说，同质品牌联合对于公司的发展战略来说意义不大，如果品牌联合异质性较大，品牌联合发行起初可能会吸引眼球，赚取热度，收获许多受众；对于品牌资产不对等的双方来说，影响也不尽相同，但后期消费者感知的功能和形式方面的异质性过于突出，可能会引起消费者的排斥心理，进而降低消费者评价。企业可以通过提升联合产品在功能和形式方面的交融整合度，产品整合度高时消费者更加容易理解品牌联合的意义和价值，也能够避免品牌联合带来的不适感，降低消费者对冲击固有认知的排斥，进而更加理解品牌融合的真正目的以及给自身带来的价值，有利于提升消费者对品牌联合的认同感，对品牌联合做出积极评价，将不匹配产品转换为一次具有创新意义的匹配产品。最后，如果将跨界产品匹配性作为消费者是否接受的前提条件，那么整合度的提升将有益于消费者从中感受到该跨界联合所带来的综合价值。好的品牌联合除了考虑前期双方的联合匹配度，也要形成良好的产品整合度，如果前期的匹配度不能达到预期，那么可以通过后期从产品和功能方面对匹配联合整合度进行调整，从而激发消费者的购买意愿以及对该品牌联合的积极评价。所以企业在实践中要注意消费者感知价值在产品整合度对品牌联合评价中的中介作用，通过良好的整合促使消费者感知产品价值，进而提升品牌联合评价。 References Voineskos, D., Daskalakis, Z.J. and Blumberger, D.M. (2020) Management of Treatment-Resistant Depression: Challenges and Strategies. Neuropsychiatric Disease and Treatment, 16, 221-234. >https://doi.org/10.2147/ndt.s198774 Pandarakalam, J.P. (2018) Challenges of Treatment-Resistant Depression. Psychiatria Danubina, 30, 273-284. >https://doi.org/10.24869/psyd.2018.273 Lenze, E.J., Mulsant, B.H., Blumberger, D.M., Karp, J.F., Newcomer, J.W., Anderson, S.J., et al. (2015) Efficacy, Safety, and Tolerability of Augmentation Pharmacotherapy with Aripiprazole for Treatment-Resistant Depression in Late Life: A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 386, 2404-2412. >https://doi.org/10.1016/s0140-6736(15)00308-6 Caldiroli, A., Capuzzi, E., Tagliabue, I., Capellazzi, M., Marcatili, M., Mucci, F., et al. (2021) Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. International Journal of Molecular Sciences, 22, Article 13070. >https://doi.org/10.3390/ijms222313070 Nuñez, N.A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M.G., Prokop, L.J., et al. (2022) Augmentation Strategies for Treatment Resistant Major Depression: A Systematic Review and Network Meta-Analysis. Journal of Affective Disorders, 302, 385-400. >https://doi.org/10.1016/j.jad.2021.12.134 Shad, M.U. (2023) Seventy Years of Antipsychotic Development: A Critical Review. Biomedicines, 11, Article 130. >https://doi.org/10.3390/biomedicines11010130 Connolly, K.R. and Thase, M.E. (2011) If at First You Donʼt Succeed. Drugs, 71, 43-64. >https://doi.org/10.2165/11587620-000000000-00000 Chow, N., Gallo, L. and Busse, J.W. (2018) Evidence-Based Medicine and Precision Medicine: Complementary Approaches to Clinical Decision-Making. Precision Clinical Medicine, 1, 60-64. >https://doi.org/10.1093/pcmedi/pby009 Kent, D.M., Steyerberg, E. and van Klaveren, D. (2018) Personalized Evidence Based Medicine: Predictive Approaches to Heterogeneous Treatment Effects. BMJ, 363, k4245. >https://doi.org/10.1136/bmj.k4245 Lesko, L. and Atkinson, A. (2001) Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, Strategies. Annual Review of Pharmacology and Toxicology, 41, 347-366. >https://doi.org/10.1146/annurev.pharmtox.41.1.347 Muth, C., Blom, J.W., Smith, S.M., Johnell, K., Gonzalez‐Gonzalez, A.I., Nguyen, T.S., et al. (2018) Evidence Supporting the Best Clinical Management of Patients with Multimorbidity and Polypharmacy: A Systematic Guideline Review and Expert Consensus. Journal of Internal Medicine, 285, 272-288. >https://doi.org/10.1111/joim.12842 Gemignani, F., Brindani, and Vitetta F, (2009) Restless Legs Syndrome: Differential Diagnosis and Management with Pramipexole. Clinical Interventions in Aging, 4, 305-313. >https://doi.org/10.2147/cia.s4143 Tundo, A., Betro’, S., Iommi, M. and de Filippis, R. (2022) Efficacy and Safety of 24-Week Pramipexole Augmentation in Patients with Treatment Resistant Depression. a Retrospective Cohort Study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 112, Article 110425. >https://doi.org/10.1016/j.pnpbp.2021.110425 Tundo, A., de Filippis, R., Felici, R., Lucangeli, C. and Iommi, M. (2025) Pramipexole Augmentation for Treatment-Resistant Unipolar Depression Not Responding to Aripiprazole Augmentation: An Observational Study. Journal of Clinical Psychopharmacology, 45, 236-242. >https://doi.org/10.1097/JCP.0000000000001986 Szabadi, E. (2024) Three Paradoxes Related to the Mode of Action of Pramipexole: The Path from D2/D3 Dopamine Receptor Stimulation to Modification of Dopamine-Modulated Functions. Journal of Psychopharmacology, 38, 581-596. >https://doi.org/10.1177/02698811241261022 Whitton, A.E., Reinen, J.M., Slifstein, M., Ang, Y., McGrath, P.J., Iosifescu, D.V., et al. (2020) Baseline Reward Processing and Ventrostriatal Dopamine Function Are Associated with Pramipexole Response in Depression. Brain, 143, 701-710. >https://doi.org/10.1093/brain/awaa002 Ferraiolo, M. and Hermans, E. (2023) The Complex Molecular Pharmacology of the Dopamine D 2 Receptor: Implications for Pramipexole, Ropinirole, and Rotigotine. Pharmacology&Therapeutics, 245, Article 108392. >https://doi.org/10.1016/j.pharmthera.2023.108392 Cortés, A., Moreno, E., Rodríguez-Ruiz, M., Canela, E.I. and Casadó, V. (2016) Targeting the Dopamine D3 Receptor: An Overview of Drug Design Strategies. Expert Opinion on Drug Discovery, 11, 641-664. >https://doi.org/10.1080/17460441.2016.1185413 Kvernmo, T., Houben, J. and Sylte, I. (2008) Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists. Current Topics in Medicinal Chemistry, 8, 1049-1067. >https://doi.org/10.2174/156802608785161457 Pacher, P. and Kecskemeti, V. (2004) Trends in the Development of New Antidepressants. Is There a Light at the End of the Tunnel? Current Medicinal Chemistry, 11, 925-943. >https://doi.org/10.2174/0929867043455594 Dragonieri, S., Portacci, A., Quaranta, V.N. and Carpagnano, G.E. (2024) Advancing Care in Severe Asthma: The Art of Switching Biologics. Advances in Respiratory Medicine, 92, 110-122. >https://doi.org/10.3390/arm92020014 Karam, S., Gebreil, A., Alksas, A., Balaha, H.M., Khalil, A., Ghazal, M., et al. (2024) Insights into Personalized Care Strategies for Wilms Tumor: A Narrative Literature Review. Biomedicines, 12, Article 1455. >https://doi.org/10.3390/biomedicines12071455 Mabrouk, O.M., Hady, D.A.A. and Abd El-Hafeez, T. (2024) Machine Learning Insights into Scapular Stabilization for Alleviating Shoulder Pain in College Students. Scientific Reports, 14, Article No. 28430. >https://doi.org/10.1038/s41598-024-79191-8 Alizadehsani, R., Roshanzamir, M., Hussain, S., Khosravi, A., Koohestani, A., Zangooei, M.H., et al. (2024) Handling of Uncertainty in Medical Data Using Machine Learning and Probability Theory Techniques: A Review of 30 Years (1991-2020). Annals of Operations Research, 339, 1077-1118. >https://doi.org/10.1007/s10479-021-04006-2 Orphanidou, C. and Wong, D. (2017) Machine Learning Models for Multidimensional Clinical Data. In: Khan, S., Zomaya, A. and Abbas, A. Eds., Scalable Computing and Communications, Springer International Publishing, 177-216. >https://doi.org/10.1007/978-3-319-58280-1_8 Adlung, L., Cohen, Y., Mor, U. and Elinav, E. (2021) Machine Learning in Clinical Decision Making. Med, 2, 642-665. >https://doi.org/10.1016/j.medj.2021.04.006 Shehab, M., Abualigah, L., Shambour, Q., Abu-Hashem, M.A., Shambour, M.K.Y., Alsalibi, A.I., et al. (2022) Machine Learning in Medical Applications: A Review of State-of-the-Art Methods. Computers in Biology and Medicine, 145, Article 105458. >https://doi.org/10.1016/j.compbiomed.2022.105458 Houssein, E.H., Hosney, M.E., Emam, M.M., Younis, E.M.G., Ali, A.A. and Mohamed, W.M. (2023) Soft Computing Techniques for Biomedical Data Analysis: Open Issues and Challenges. Artificial Intelligence Review, 56, 2599-2649. >https://doi.org/10.1007/s10462-023-10585-2 Ahmad, T., Lund, L.H., Rao, P., Ghosh, R., Warier, P., Vaccaro, B., et al. (2018) Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. Journal of the American Heart Association, 7, e008081. >https://doi.org/10.1161/jaha.117.008081 Gordon, A.C., Alipanah-Lechner, N., Bos, L.D., Dianti, J., Diaz, J.V., Finfer, S., et al. (2024) From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations for Developing Precision Medicine in the ICU. American Journal of Respiratory and Critical Care Medicine, 210, 155-166. >https://doi.org/10.1164/rccm.202311-2086so Oxman, A.D. and Guyatt, G.H. (1992) A Consumer’s Guide to Subgroup Analyses. Annals of Internal Medicine, 116, 78-84. >https://doi.org/10.7326/0003-4819-116-1-78 Barsevick, A.M. (2007) The Elusive Concept of the Symptom Cluster. Oncology Nursing Forum, 34, 971-980. >https://doi.org/10.1188/07.onf.971-980 Pamulaparthyvenkata, S., Reddy, S.G. and Singh, S. (2023) Leveraging Technological Advancements to Optimize Healthcare Delivery: A Comprehensive Analysis of Value-Based Care, Patient-Centered Engagement, and Personalized Medicine Strategies. Journal of AI-Assisted Scientific Discovery, 3, 371-378. Adeghe, E.P., Okolo, C.A. and Ojeyinka, O.T. (2024) The Role of Big Data in Healthcare: A Review of Implications for Patient Outcomes and Treatment Personalization. World Journal of Biology Pharmacy and Health Sciences, 17, 198-204. >https://doi.org/10.30574/wjbphs.2024.17.3.0133 Anuyah, Sydney, Singh, M.K. and Nyavor, H. (2024) Advancing Clinical Trial Out-Comes Using Deep Learning and Predictive Modelling: Bridging Precision Medicine and Patient-Centered Care. arXiv:2412.07050. Thoppil, I.J., Ashtalakshmi, K. and Chundi, R. (2025) Transforming Healthcare. In: Sharma, M., Sharma, D.K., Agarwal, D. and Harthy, K.A., Eds., Bioinformatics and Beyond, CRC Press, 92-114. >https://doi.org/10.1201/9781003508403-5 Sahin, E.K. (2020) Assessing the Predictive Capability of Ensemble Tree Methods for Landslide Susceptibility Mapping Using XGBoost, Gradient Boosting Machine, and Random Forest. SN Applied Sciences, 2, Article No. 1308. >https://doi.org/10.1007/s42452-020-3060-1 Nawar, S. and Mouazen, A. (2017) Comparison between Random Forests, Artificial Neural Networks and Gradient Boosted Machines Methods of On-Line Vis-NIR Spectroscopy Measurements of Soil Total Nitrogen and Total Carbon. Sensors, 17, Article 2428. >https://doi.org/10.3390/s17102428 Jafarzadeh, H., Mahdianpari, M., Gill, E., Mohammadimanesh, F. and Homayouni, S. (2021) Bagging and Boosting Ensemble Classifiers for Classification of Multispectral, Hyperspectral and PoLSAR Data: A Comparative Evaluation. Remote Sensing, 13, Article 4405. >https://doi.org/10.3390/rs13214405 Gaye, B. and Wulamu, A. (2019) Sentiment Analysis of Text Classification Algorithms Using Confusion Matrix. In: Ning, H., Ed., Communications in Computer and Information Science, Springer Singapore, 231-241. >https://doi.org/10.1007/978-981-15-1922-2_16 Obi, J.C. (2023) A Comparative Study of Several Classification Metrics and Their Performances on Data. World Journal of Advanced Engineering Technology and Sciences, 8, 308-314. >https://doi.org/10.30574/wjaets.2023.8.1.0054 Laatifi, M., Douzi, S., Ezzine, H., Asry, C.E., Naya, A., Bouklouze, A., et al. (2023) Explanatory Predictive Model for COVID-19 Severity Risk Employing Machine Learning, Shapley Addition, and Lime. Scientific Reports, 13, Article No. 5481. >https://doi.org/10.1038/s41598-023-31542-7 Miao, K., Houssou Hounye, A., Su, L., Pan, Q., Wang, J., Hou, M., et al. (2024) Exploring Explainable Machine Learning and Shapley Additive Explanations (SHAP) Technique to Uncover Key Factors of HNSC Cancer: An Analysis of the Best Practices. Biomedical Signal Processing and Control, 89, Article 105752. >https://doi.org/10.1016/j.bspc.2023.105752 Upadhyaya, D.P., Tarabichi, Y., Prantzalos, K., Ayub, S., Kaelber, D.C. and Sahoo, S.S. (2024) Machine Learning Interpretability Methods to Characterize the Importance of Hematologic Biomarkers in Prognosticating Patients with Suspected Infection. Computers in Biology and Medicine, 183, Article 109251. >https://doi.org/10.1016/j.compbiomed.2024.109251 Raptis, S., Ilioudis, C. and Theodorou, K. (2024) From Pixels to Prognosis: Unveiling Radiomics Models with SHAP and LIME for Enhanced Interpretability. Biomedical Physics&Engineering Express, 10, Article 035016. >https://doi.org/10.1088/2057-1976/ad34db Grzenda, A., Speier, W., Siddarth, P., Pant, A., Krause-Sorio, B., Narr, K., et al. (2021) Machine Learning Prediction of Treatment Outcome in Late-Life Depression. Frontiers in Psychiatry, 12, Article 738494. >https://doi.org/10.3389/fpsyt.2021.738494 Park, J., Kim, J., Ryu, D. and Choi, H. (2023) Factors Related to Steroid Treatment Responsiveness in Thyroid Eye Disease Patients and Application of SHAP for Feature Analysis with XGBoost. Frontiers in Endocrinology, 14, Article 1079628. >https://doi.org/10.3389/fendo.2023.1079628 Shalimova, A., Babasieva, V., Chubarev, V.N., Tarasov, V.V., Schiöth, H.B. and Mwinyi, J. (2021) Therapy Response Prediction in Major Depressive Disorder: Current and Novel Genomic Markers Influencing Pharmacokinetics and Pharmacodynamics. Pharmacogenomics, 22, 485-503. >https://doi.org/10.2217/pgs-2020-0157 Stocchi, F., Bravi, D., Emmi, A. and Antonini, A. (2024) Parkinson Disease Therapy: Current Strategies and Future Research Priorities. Nature Reviews Neurology, 20, 695-707. >https://doi.org/10.1038/s41582-024-01034-x Blackburn, T.P. (2019) Depressive Disorders: Treatment Failures and Poor Prognosis over the Last 50 Years. Pharmacology Research&Perspectives, 7, e00472. >https://doi.org/10.1002/prp2.472 Vaughn, D.A., Marino, B., Engelbertson, A., Dojnov, A., Weiss, N., Vila-Rodriguez, F., Nanos, G. and Downar, J. (2024) Real-World Effectiveness of A single-Day Regimen for Transcranial Magnetic Stimulation Using Optimized, Neuroplastogen-Enhanced Techniques in Depression (ONE-D). >https://doi.org/10.21203/rs.3.rs-5679327/v1 Zanetti, M.V., Loch, A. and Machado-Vieira, R. (2015) Translating Biomarkers and Biomolecular Treatments to Clinical Practice. In: Yildiz, A., Ruiz, P. and Nemeroff, C., Eds., The Bipolar Book, Oxford University Press, 149-168. >https://doi.org/10.1093/med/9780199300532.003.0013 Fabbri, C. (2025) Treatment-Resistant Depression: Role of Genetic Factors in the Perspective of Clinical Stratification and Treatment Personalisation. Molecular Psychia-try, 30, 2210-2218. Prompiengchai, S. and Dunlop, K. (2024) Breakthroughs and Challenges for Generating Brain Network-Based Biomarkers of Treatment Response in Depression. Neuropsychopharmacology, 50, 230-245. >https://doi.org/10.1038/s41386-024-01907-1 Sforzini, L., Worrell, C., Kose, M., Anderson, I.M., Aouizerate, B., Arolt, V., et al. (2021) A Delphi-Method-Based Consensus Guideline for Definition of Treatment-Resistant Depression for Clinical Trials. Molecular Psychiatry, 27, 1286-1299. >https://doi.org/10.1038/s41380-021-01381-x Cook, N., Hansen, A.R., Siu, L.L. and Abdul Razak, A.R. (2014) Early Phase Clinical Trials to Identify Optimal Dosing and Safety. Molecular Oncology, 9, 997-1007. >https://doi.org/10.1016/j.molonc.2014.07.025 Poweleit, E.A., Vinks, A.A. and Mizuno, T. (2023) Artificial Intelligence and Machine Learning Approaches to Facilitate Therapeutic Drug Management and Model-Informed Precision Dosing. Therapeutic Drug Monitoring, 45, 143-150. >https://doi.org/10.1097/ftd.0000000000001078 Tyson, R.J., Park, C.C., Powell, J.R., Patterson, J.H., Weiner, D., Watkins, P.B., et al. (2020) Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables. Frontiers in Pharmacology, 11, Article 420. >https://doi.org/10.3389/fphar.2020.00420 Maristany, A.J., Sa, B.C., Murray, C., Subramaniam, A.B. and Oldak, S.E. (2024) Psychiatric Manifestations of Neurological Diseases: A Narrative Review. Cureus, 16, e64152. >https://doi.org/10.7759/cureus.64152 Bernatoniene, J., Plieskis, M. and Petrikonis, K. (2025) Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies. Pharmaceutics, 17, Article 352. >https://doi.org/10.3390/pharmaceutics17030352 Olanow, C.W., Watts, R.L. and Koller, W.C. (2001) An Algorithm (Decision Tree) for the Management of Parkinson’s Disease (2001): Treatment Guidelines. Neurology, 56, S1-S88. >https://doi.org/10.1212/wnl.56.suppl_5.s1 Shi, H., Zhang, M., Mujumdar, A.S. and Li, C. (2024) Potential of 3D Printing in Development of Foods for Special Medical Purpose: A Review. Comprehensive Reviews in Food Science and Food Safety, 23, e70005. >https://doi.org/10.1111/1541-4337.70005 Brown, L.C., Mueller, D.J., Eyre, H.A., Bousman, C. and Greden, J.F. (2022) Tools to Aid Precision Treatments to Prevent or Manage Treatment-Resistant Depression (TRD): Pharmacogenomics, Machine Learning, and Artificial Intelligence. In: Quevedo, J., Riva-Posse, P. and Bobo, W.V., Eds., Managing Treatment-Resistant Depression, Academic Press, 99-105. Marano, G., Rossi, S., Sfratta, G., Traversi, G., Lisci, F.M., Anesini, M.B., et al. (2025) Gut Microbiota: A New Challenge in Mood Disorder Research. Life, 15, Article 593. >https://doi.org/10.3390/life15040593